Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190400015667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis.
ACS Appl Mater Interfaces
January 2025
School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 999077, China.
Article Synopsis
- Ovarian cancer is the most deadly gynecological cancer, with current chemotherapy often ineffective due to drug resistance, especially in advanced stages.
- A new treatment using a nanoformulation called Bola/IM targets ovarian cancer stem cells (CSCs) more effectively than imatinib alone, utilizing a specific mechanism to inhibit cancer growth and spread.
- The Bola/IM formulation shows promising results in lab models and enhances the effectiveness of cisplatin, making it a strong candidate for improving treatment for metastatic ovarian cancer.
Integrative analyses of mendelian randomization and bioinformatics reveal casual relationship and genetic links between COVID-19 and knee osteoarthritis.
BMC Med Genomics
January 2025
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.
Background: Clinical and epidemiological analyses have found an association between coronavirus disease 2019 (COVID-19) and knee osteoarthritis (KOA). Infection with COVID-19 may increase the risk of developing KOA.
Objectives: This study aimed to investigate the potential causal relationship between COVID-19 and KOA using Mendelian randomization (MR) and to explore the underlying mechanisms through a systematic bioinformatics approach.
[Synergistic Effect of IGF1-R Inhibitor AEW541 on Imatinib Inducing SUP-B15 Cell Death].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Blood Diseases Institute, Xuzhou Medical University, Department of Hematology, The Affiliated Hospital of Xuzhou Medical University.
Objective: To explore whether Ph acute lymphoblastic leukemia (ALL) cell line SUP-B15 treated with imatinib occurs a tolerant status charactered by cell proliferation suppression but apoptotic resistance, then evaluate whether IGF1-R inhibitor AEW541 can break this tolerance, and further explain its mechanisms.
Methods: SUP-B15 cells were treated with different concentrations of imatinib or AEW541. Cell proliferation was assayed by Deep Blue, and apoptotic cells were determined by Annexin V/7-AAD staining.
Complex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/ Rearrangement, Mutation, and Transient Chimera.
Cancer Genomics Proteomics
December 2024
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;
Background/aim: Myelodysplastic syndromes (MDSs) are clonal bone marrow disorders characterized by ineffective hematopoiesis. They are classified based on morphology and genetic alterations, with SF3B1 variants linked to favorable prognosis and MECOM rearrangements associated with poor outcomes. The combined effects of these alterations remain unclear.
View Article and Find Full Text PDFNovel Treatment Strategies for Chronic Myeloid Leukemia.
Blood
December 2024
Versiti Blood Research Institute, Milwaukee, Wisconsin, United States.
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!